FIBROGEN INC - COMMON STOCK

FibroGen Appoints David DeLucia as Chief Financial Officer

16 Dec 2024 08:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

13 Nov 2024 15:58:52 By NetDania Notify

FibroGen Reports Third Quarter 2024 Financial Results

12 Nov 2024 16:05:02 By Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2024 Financial Results

04 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

31 Oct 2024 16:00:39 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

28 Oct 2024 10:16:28 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

09 Oct 2024 10:58:40 By NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

08 Oct 2024 09:46:54 By NetDania Notify

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

03 Sep 2024 12:45:29 By NetDania Notify

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 16:05:02 By Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2024 Financial Results

30 Jul 2024 16:07:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

30 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

18 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

03 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

03 Jun 2024 16:02:00 By Nasdaq GlobeNewswire

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

23 May 2024 17:05:00 By Nasdaq GlobeNewswire

FibroGen to Participate in Upcoming Investor Conferences

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2024 Financial Results

06 May 2024 16:02:00 By Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2024 Financial Results

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire